As presented last week, Genticel was getting back on track with the announcement of two major milestones with the aim to prepare the phase III. However, the major outcomes of its Phase II were expected to be presented on the 17th of June at Eurogin 2016 Congress… Here they are (and they are really bad)!
GTL001 is designed to target and clear strain 16 & 18 of the Human Papillomavirus (HPV) from an infected body and avoid the development of cervical cancer, theoretically… Unfortunately, it seems like the treatment has some lack of activity. Indeed, the vaccine did not show any significant difference compared to the placebo.
The Phase II trial enrolled 233 patients – 117 have received two injections of 600 µg vaccines within 6 weeks and 116 the placebo with the same posology. After 18 months results showed that the clearance (elimination of the virus from the body) wasn’t higher in the first group than in the second one.